EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates

Xia Wu iD, Heather Landau iD, Jennifer E Liu iD, Yihan Cao iD, Raymond L Comenzo iD

CA: A Cancer Journal for Clinicians · 2026-05 · 76 (3)

DOI: 10.3322/caac.70092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 08.06.2026. Verfasst von Xia Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Medicine Myeloma and Amyloid Program, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis. Die Arbeit nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic immunoglobulin light‐chain amyloidosis is a rare but life‐threatening plasma cell disorder characterized by the production of misfolded monoclonal light chains that deposit as amyloid fibrils, leading to pathologic tissue remodeling and progressive multiorgan dysfunction. Despite substantial therapeutic advances, delayed diagnosis remains common because of nonspecific presentations and the need for coordinated hematologic, pathologic, and organ‐specific evaluation. The introduction of daratumumab‐based regimens has transformed frontline therapy, whereas advances in cytogenetic profiling, measurable residual disease assessment, and transplantation strategies have informed risk‐adapted management. Emerging treatments, including BCL‐2–targeted therapy, bispecific antibodies, chimeric antigen receptor T‐cell therapy, and possibly fibril‐directed approaches, further expand the therapeutic landscape. This review summarizes contemporary concepts in the pathobiology, diagnosis, and management of systemic light‐chain amyloidosis, with an emphasis on practical diagnostic algorithms, evolving response assessment, and remaining challenges in achieving durable organ recovery and sustained survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisHumans

Stichwörter der Autor:innen

amyloid organsamyloid treatment, cardiac amyloidosislight chain amyloidosis

Autor:innen und Institutionen

  • Tufts Medicine Myeloma and Amyloid Program, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Cardiology Service, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Hematology Oncology, Tufts Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Xia Wu, Heather Landau, Jennifer E Liu, Yihan Cao, Raymond L Comenzo

Förderung

  • NCI NIH HHS
  • Division of Cancer Prevention, National Cancer Institute

Zitieren

APA

Wu, X., Landau, H., Liu, J. E., Cao, Y., & Comenzo, R. L. (2026). Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates. CA: A Cancer Journal for Clinicians, 76(3). https://doi.org/10.3322/caac.70092

Vancouver

Wu X, Landau H, Liu JE, Cao Y, Comenzo RL. Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates. CA: A Cancer Journal for Clinicians. 2026;76(3). doi:10.3322/caac.70092

BibTeX
@article{Wu2026,
  author = {Wu, Xia and Landau, Heather and Liu, Jennifer E and Cao, Yihan and Comenzo, Raymond L},
  title = {Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {3},
  doi = {10.3322/caac.70092}
}
Kostenlos starten →